Tag Archives: European Medicines Agency

February, 2016

October, 2015

  • 19 October

    Clinical Perspectives of Biosimilars in Rheumatology

    Drugs produced using biotechnology are among the most expensive medicines available. Biosimilars that offer a real alternative are becoming increasingly available on the market. The promise of biosimilars is that, once patent protection has elapsed for established biologics, more patients will be able to access effective and well-tolerated drugs. This …